rs143218168
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 3P and 1B. PM1PP5BP4
The NM_000275.3(OCA2):c.1255C>T(p.Arg419Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000267 in 1,613,774 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R419Q) has been classified as Benign.
Frequency
Consequence
NM_000275.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
OCA2 | NM_000275.3 | c.1255C>T | p.Arg419Trp | missense_variant | 13/24 | ENST00000354638.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
OCA2 | ENST00000354638.8 | c.1255C>T | p.Arg419Trp | missense_variant | 13/24 | 1 | NM_000275.3 | P1 | |
OCA2 | ENST00000353809.9 | c.1183C>T | p.Arg395Trp | missense_variant | 12/23 | 1 |
Frequencies
GnomAD3 genomes AF: 0.000512 AC: 78AN: 152216Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000219 AC: 54AN: 246900Hom.: 0 AF XY: 0.000179 AC XY: 24AN XY: 133832
GnomAD4 exome AF: 0.000242 AC: 353AN: 1461440Hom.: 0 Cov.: 34 AF XY: 0.000235 AC XY: 171AN XY: 726986
GnomAD4 genome AF: 0.000512 AC: 78AN: 152334Hom.: 0 Cov.: 32 AF XY: 0.000470 AC XY: 35AN XY: 74496
ClinVar
Submissions by phenotype
not provided Pathogenic:2Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 09, 2023 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31229681, 9259203, 30025130, 30414346, 34426522, 31077556, 32552135, 34707637, 33124154, 34838614, 33808351, 37194472, 35488210) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 01, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 419 of the OCA2 protein (p.Arg419Trp). This variant is present in population databases (rs143218168, gnomAD 0.2%). This missense change has been observed in individual(s) with oculocutaneous albinism (PMID: 9259203, 21458243, 29345414, 31077556). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 194160). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt OCA2 protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Tyrosinase-positive oculocutaneous albinism Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 06, 2021 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with brown oculocutaneous and oculocutaneous, type II albinism (MIM#203200). (I) 0106 - This gene is associated with autosomal recessive disease. A single variant has been reported in two families with dominant oculocutaneous albinism (PMID: 32741191). (I) 0115 - Variants in this gene causing oculocutaneous albininism are known to have variable expressivity (PMID: 24518832). (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to tryptophan. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v3) <0.01 for a recessive condition (78 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (12158 heterozygotes, 400 homozygotes). (I) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated permease P domain (NCBI). (I) 0710 - Another missense variant has inconclusive previous evidence for pathogenicity. This alternative change at the same position (p.Arg419Gln) has been reported multiple times as benign and as a polymorphism, but has a weaker Grantham change (LOVD, ClinVar, PMID: 9259203). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been previously reported as a VUS (ClinVar), but more recently described as pathogenic and observed in many compound heterozygous patients with oculocutaneous albinism (PMID: 9259203, PMID: 33124154; PMID: 23504663; PMID: 31229681; PMID: 29095814; PMID: 31077556). One patient also had occult macular dystrophy, but this is due to an additional variant in the RPL1L1 gene (PMID: 30025130). (SP) 1102 - Strong phenotype match for this individual. (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 24, 2024 | - - |
OCA2-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 30, 2024 | The OCA2 c.1255C>T variant is predicted to result in the amino acid substitution p.Arg419Trp. This variant has been reported in individuals with autosomal recessive oculocutaneous albanism (OCA) (Spritz et al. 1997. PubMed ID: 9259203; Zobor et al. 2018. PubMed ID: 30025130; Zhong et al. 2019. PubMed ID: 31077556). This variant is reported in 0.21% of alleles in individuals of African descent in gnomAD. This variant is interpreted as likely pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at